NOX4 and Related Biomarkers in ADPKD

Mayo Clinic

Overview

The purpose of this study is to determine the value of NOX4, markers of mitochondria injury and function, and oxidative stress as real-time biomarkers to assess disease severity in patients with early ADPKD . The study is observational and participants will not be asked to take an investigational drug or therapy.

This will be a cross sectional study and will include male and female, young (18-40-years) well characterized patients with early (eGFR>90mL/min/1.73m2) ADPKD. Patients with different classes of disease severity will be selected using the ADPKD imaging classification. The study will include 60 class-1 (A-E) patients (N=12 per each sub-class).

During the study period, patients will be asked to provide blood and urine samples to determine biomarkers of oxidative status and mitochondrial injury in early stages of the disease. In addition, an abdominal MRI will be performed to determine patient’s total kidney volume (TKV).

 

You may be eligible for this study if you:

  • 18-40 years of age
  • Have been diagnosed with ADPKD
  • Have a lab value eGFR greater than 90 mL/min/1.73 m2

 

Exclusion criteria:

  • Unable to undergo an MRI
  • Kidney or any other solid organ transplant recipient or a planned transplant during the study
  • Currently taking tolvaptan
  • Other eligibility criteria may apply

 

Locations

Minnesota